Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Wall Street's Biggest Novo Nordisk Bear Just Flipped--Here's Why He Says It's Time to Buy
After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.
Clinical Pain Advisor23h
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
The GLP-1 shortages are over. What happens next?
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
The drugstore industry is struggling. Here's what could be in its future.
But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...
Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...